Congestive heart failure in chronic kidney disease: Disease-specific mechanisms of systolic and diastolic heart failure and management

Cardiology Clinics

Volumn 23, Issue 3, 2005, Pages 275-284

  Curtis, Bryan M ^a   Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; THIAZIDE DIURETIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIALYSIS; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG POTENTIATION; DYSLIPIDEMIA; FAMILY HISTORY; HEALTH CARE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPOALBUMINEMIA; HYPOTENSION; IMMOBILIZATION; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MALNUTRITION; MASCULINITY; MENOPAUSE; MENTAL STRESS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENESCENCE; SMOKING; STROKE; SYSTOLE; THROMBOSIS;

CARDIOMYOPATHIES; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RISK FACTORS;

EID: 23244457401     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2005.04.002     Document Type: Review

References (103)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 2 2002 S1 S266
2. B.A. Kiberd, and C.M. Clase Kidney Disease Outcome Quality Initiative J Am Soc Nephrol 13 2002 1635 1644
3. R. Goeree, J. Manalich, and P. Grootendorst Cost analysis of dialysis treatments for end-stage renal disease (ESRD) Clin Invest Med 18 6 1995 455 464
4. H. Lee, B. Manns, and K. Taub Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access Am J Kidney Dis 40 3 2002 611 622
5. US Renal Data System USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2003 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda (MD)
6. A.R. Nissenson, B.J. Periera, and A.J. Collins Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization Am J Kidney Dis 37 2001 1177 1183
7. B.F. Culleton, M.G. Larson, and J.C. Evans Prevalence and correlates of elevated serum creatinine levels Arch Intern Med 159 1999 1785 1790
8. J. Coresh, G.L. Wei, and G. McQuillan Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 161 2001 1207 1216
9. C.M. Clase, A.X. Garg, and B.A. Kiberd Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Survey (NHANES III) J Am Soc Nephrol 13 2002 1338 1349
10. C.-Y. Hsu, G.M. Chertow, and G.C. Curhan Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency Kidney Int 61 2002 1567 1576
11. J. Coresh, B.C. Astor, and T. Greene Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 1 2003 1 12
12. B.F. Culleton, M.G. Larson, and P.W.F. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
13. J.M. Lazarus, E.G. Lowrie, and C.L. Hampers Cardiovascular disease in uremic patients on hemodialysis Kidney Int Suppl 2 1975 167 175
14. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 12 Suppl 1998 S16 S23
15. G. London, and P.S. Parfrey Cardiac disease in chronic uremia: pathogenesis Adv Ren Replace Ther 4 1997 194 211
16. C. Rigatto, P. Parfrey, and R. Foley Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease J Am Soc Nephrol 13 4 2002 1084 1090
17. P.S. Parfrey, R.N. Foley, and J.D. Harnett Outcome and risk factors for left ventricular disorders in chronic uremia Nephrol Dial Transplant 11 1996 1277 1285
18. R.N. Foley, P.S. Parfrey, and G.M. Kent Longterm evolution of cardiomyopathy in dialysis patients Kidney Int 54 1998 1720 1725
19. A. Levin, C.R. Thompson, and J. Ethier Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 1999 125 134
20. C. Rigatto, R.N. Foley, and G.M. Kent Long-term changes in left ventricular hypertrophy after renal transplantation Transplantation 2000 570 575 27;70(4)
21. R.G. Rostand, K.A. Kirk, and E.A. Rutsky Dialysis ischemic heart disease: insights from coronary angiography Kidney Int 25 1984 653 659
22. P.S. Parfrey Pathogenesis of cardiac disease in dialysis patients Semin Dial 12 1999 62 68
23. R.N. Foley, B.F. Culleton, and P.S. Parfrey Cardiac disease in diabetic end-stage renal disease Diabetologia 40 11 1997 1307 1312
24. G.M. London, A.P. Guerin, and S.J. Marchais Hemodynamic overload in end-stage renal disease patients Semin Dial 12 1999 77 83
25. R.N. Foley, P.S. Parfrey, and J.D. Harnett Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 1 1995 186 192
26. B.J. Barrett, P.S. Parfrey, and J. Morgan Prediction of early death in end-stage renal disease patients starting dialysis Am J Kidney Dis 29 1997 214 222
27. A. Levin, J. Singer, and C.R. Thompson Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 27 3 1996 347 354
28. Dialysis and renal transplantation Canadian Organ Replacement Register 2001, Vol. 1 2001 Canadian Institute for Health Information Ottawa (Ontario, Canada)
29. M.J. Sarnak, and A.S. Levey Cardiovascular disease and chronic renal disease: a new paradigm Am J Kidney Dis 35 4 Suppl 1 2000 S117 S131
30. S. Klahr, A.S. Levey, G.J. Beck for the Modification of Diet in Renal Disease Study Group The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease N Engl J Med 330 1994 877 884
31. L.G. Hunsicker, S. Adler, A. Caggiula for the Modification of Diet in Renal Disease Study Group Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 1997 1908 1919
32. National Kidney Foundation Task Force on Cardiovascular Disease Controlling the epidemic of cardiovascular disease in chronic renal disease Am J Kid Dis 32 Suppl 3 1998 S1 S199
33. W.K. Bolton, and A.S. Kliger Chronic renal insufficiency: current understandings and their implications Am J Kidney Dis 36 6 Suppl 3 2000 S4 S12
34. M.J. Sarnak, and A.S. Levey Cardiovascular disease and chronic renal disease: a new paradigm Am J Kidney Dis 36 4 Suppl 1 2000 S117 S131
35. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kid Dis 32 Suppl 3 1998 112 119
36. M.J. Landray, J. Thambyrajah, and F.J. McGlynn Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment Am J Kidney Dis 38 2001 537 546
37. M.J. Sarnak, B.E. Coronado, and T. Greene Cardiovascular disease risk factors in chronic renal insufficiency Clin Nephrol 57 2002 327 335
38. P. Muntner, H. Jiang, and L. Hamm Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Nephrol 13 2002 745 753
39. A.X. Garg, W.F. Clark, and B. Haynes Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I Kidney Int 61 2002 1486 1494
40. L. Hansson, A. Zanchetti, S.G. Carruthers for the HOT Study Group Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762
41. R.O. Estacio, N. Gifford, and B.W. Jeffers Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
42. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
43. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
44. A.V. Chobanian, G.L. Bakris, H.R. Black and the National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2571
45. G. Bakris, M. Williams, and L. Dworkin Preserving renal function in adults with hypertension and diabetes: a consensus approach Am J Kidney Dis 36 2000 646 661
46. R.D. Toto, H.C. Mithell, and R.D. Smith Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis Kidney Int 48 1995 851 859
47. J.M. Lazarus, J.J. Bourgoignie, and V.M. Buckalew Achievement and safety of a low blood pressure goal in chronic renal disease Hypertension 29 1997 641 650
48. M.R. Weir, and L.D. Dworkin Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy? Am J Kidney Dis 32 1998 1 22
49. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
50. J.F.E. Mann, H.C. Gerstein, and J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
51. S.W. Murphy Diastolic dysfunction Curr Treat Options Cardiovasc Med 6 1 2004 61 68
52. E.J. Lewis, L.G. Hunsicker, and Bain The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1461
53. M. Ravid, H. Savin, and I. Jutrin Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 1993 577 581
54. T. Philipp, M. Anlauf, A. Distler on behalf of the HANE Trial Research Group Randomized, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study BMJ 15 1997 154 159
55. T.H. Jafar, C.H. Schmid, and M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
56. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
57. M.A. Pfeffer, E. Braunwald, and L.A. Moyé Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 327 1992 669 677
58. B.M. Brenner, M.E. Cooper, and D. deZeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
59. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
60. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 9311 2002 995 1003
61. K. Bhagat, and J.G. Hakim Why beta blockers should be used in heart failure Cent Afr J Med 45 1999 187 189
62. E. Lonn, and R. McKelvie Drug treatment in heart failure BMJ 320 2000 1188 1192
63. T.J. Ryan, J.L. Anderson, and E.M. Antman ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol 28 1996 1328 1428
64. F.A. McAlister, J. Ezekowitz, and M. Tonelli Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study Circulation 109 8 2004 1004 1009
65. A. Chrysostomou, and G. Becker Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease N Engl J Med 345 2001 925 926
66. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
67. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 1997 525 533
68. A. Levin, O. Djurdjev, and B. Barrett Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter Am J Kidney Dis 38 6 2001 1398 1407
69. G.M. London, B. Pannier, and S.J. Marchais Calcification of the aortic valve in the dialyzed patient J Am Soc Nephrol 11 2000 778 783
70. J.M. McLenachan, E. Henderson, and H.J. Dargie A possible mechanism of sudden death in hypertensive left ventricular hypertrophy J Hypertens 5 Suppl 5 1997 630
71. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy N Engl J Med 342 2000 381 389
72. Prospective Diabetes Study UK. (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
73. Prospective Diabetes Study UK (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
74. R.N. Foley, C.A. Herzog, and A.J. Collins Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study Kidney Int 63 4 2003 1462 1467
75. K. Wilson, N. Gibson, and A. Willan Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies Arch Intern Med 160 2000 939 944
76. M. Regalado, S. Yang, and D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
77. S.R. Orth, A. Stockmann, and C. Conradt Smoking as a risk factor for end-stage renal failure in men with primary renal disease Kidney Int 54 1998 926 931
78. S.R. Orth Smoking and the kidney J Am Soc Nephrol 13 2002 1663 1672
79. I. Mulder, M. Tijhuis, and H.A. Smit Smoking cessation and quality of life: the effect of amount of smoking and time since quitting Prev Med 33 2001 653 660
80. G.F. Feeney, A. McPherson, and J.P. Connor Randomized controlled trial of two cigarette quit programmes in coronary care patients after acute myocardial infarction Intern Med J 31 2001 470 475
81. M. Tonelli, L. Moye, and F.M. Sacks Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 2 2003 98 104
82. R. Collins, J. Armitage, S. Parish for the Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 2003 2005 2016 14;361(9374):
83. R. Moore Therapeutic considerations for the use of statin therapy in chronic renal disease Nephron Clin Pract 95 4 2003 c107 c115
84. R.N. Foley Anaemia and the heart: what's new in 2003? Nephrol Dial Transplant 2003 13 16 18(Suppl 8):viii
85. C.T. Jurkovitz, J.L. Abramson, and L.V. Vaccarino Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study J Am Soc Nephrol 14 11 2003 2919 2925
86. J.L. Abramson, C.T. Jurkovitz, and V. Vaccarino Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study Kidney Int 64 2 2003 610 615
87. A. Levin, J. Singer, C.R. Thompson, and H. Ross Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention Am J Kidney Dis 27 3 1996 347 354
88. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 300 1990 573 578
89. A.J. Collins, J.Z. Ma, and A. Xia Trends in anemia treatment with erythropoietin usage and patients outcomes Am J Kidney Dis 32 6 Suppl 4 1998 S133 S141
90. S. Sheingold, D. Churchill, and N. Muirhead The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada Soc Sci Med 34 1992 983 991
91. N. Powe, R.I. Griffiths, and A.J. Watson Effect of recombinant erythropoietin on hospital admission, readmission, length of stay and costs in dialysis patients J Am Soc Nephrol 4 1994 1455 1465
92. A. Martinez-Vea, A. Bardaji, and C. Garcia Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis Am J Kidney Dis 19 1992 353 357
93. D.A. Revicki, R.E. Brown, and D.H. Feeny Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients Am J Kidney Dis 25 1995 548 554
94. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
95. R.N. Foley, P.S. Parfrey, and J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 3 2000 1325 1335
96. S.D. Roger, L.P. McMahon, and A. Clarkson Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial J Am Soc Nephrol 15 1 2004 148 156
97. Foley RN, Parfrey PS, Wittreich BH, et al. The effect of higher haemoglobin levels on left ventricular cavity volume in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease (abstract MO12 presented at the European Renal Association-European Dialysis Transplant Association), Lisbon, Portugal. 2004. Available at: http://www.abstracts2view.com/era/authorindex.php. Accessed January 26, 2005.
98. A. Levin Consequences of late referral on patient outcomes Nephrol Dial Transplant 15 Suppl 3 2000 8 13
99. A.G. Stack Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States Am J Kidney Dis 41 2 2003 310 318
100. K.S. Kinchen, J. Sadler, and N. Fink The timing of specialist evaluation in chronic kidney disease and mortality Ann Intern Med 137 6 2002 479 486
101. K. McLaughlin, B. Manns, and B. Culleton An economic evaluation of early versus late referral of patients with progressive renal insufficiency Am J Kidney Dis 38 5 2001 1122 1128
102. D.C. Mendelssohn, B.J. Barrett, and L.M. Brownscombe Elevated levels of serum creatinine: recommendations for management and referral Can Med Assoc J 161 4 1999 413 417
103. W.M. McClellan, D.F. Knight, and H. Karp Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines Am J Kidney Dis 29 3 1997 368 375